Recombinant Mouse CD40 cell lysate

• Cat.No.: CD40-1831MCL
• Product Overview: Mouse CD40 / TNFRSF5 derived in Human Cells. The whole cell lysate is provided in 1X Sample Buffer.Browse all transfected cell lysate positive controls

Specification

• Source: Human cells
• Species: Mouse
• Preparation method: Transfected cells were cultured for 48hrs before collection. The cells were lysed in modified RIPA buffer with cocktail of protease inhibitors. Cell debris was removed by centrifugation and then centrifuged to clarify the lysate. The cell lysate was boiled for 5 minutes in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.
• Lysis buffer: Modified RIPA Lysis Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
• Quality control Testing: 12.5% SDS-PAGE Stained with Coomassie Blue
• Recommended Usage: 1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.2. Re-dissolve the pellet using 200μL pure water and boiled for 2-5 min.3. Store it at -80°C. Recommend to aliquot the cell lysate into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.Notes:The lysate is ready to load on SDS-PAGE for Western blot application. If dissociating conditions are required, add reducing agent prior to heating.
• Stability: Samples are stable for up to twelve months from date of receipt at -80°C
• Storage Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
• Storage Instruction: Lysate samples are stable for 12 months from date of receipt when stored at -80°C. Avoid repeated freeze-thaw cycles. Prior to SDS-PAGE fractionation, boil the lysate for 5 minutes.
• Tag: Non

Gene Information

• Gene Name: Cd40 CD40 antigen [ Mus musculus ]
• Official Symbol: CD40
• Synonyms: CD40; CD40 antigen; tumor necrosis factor receptor superfamily member 5; CD40L receptor; B-cell surface antigen CD40; T-cell differentiation antigen; tumor necrosis factor receptor superfamily, member 5; IGM; p50; Bp50; GP39; IMD3; TRAP; HIGM1; T-BAM; Tnfrsf5; AI326936
• Gene ID: 21939
• mRNA Refseq: NM_011611
• Protein Refseq: NP_035741
• Pathway: Adaptive Immune System, organism-specific biosystem; Allograft rejection, organism-specific biosystem; Allograft rejection, conserved biosystem; Asthma, organism-specific biosystem; Asthma, conserved biosystem; Autoimmune thyroid disease, organism-specific biosystem; Autoimmune thyroid disease, conserved biosystem
• Function: binding; enzyme binding; protein binding; receptor activity

Reviews

10/28/2021

Its utilization in this technique has allowed for precise visualization and determination of protein structures with remarkable clarity and resolution.

08/11/2021

The reliable and high-quality results obtained using CD40 protein make it an excellent choice for researchers studying protein structures.

10/07/2018

CD40 protein has proved to be an invaluable tool in protein electron microscopy structure analysis.

Q&As

Can CD40-targeted therapies be used in the treatment of infectious diseases?

CD40 agonists have the potential to enhance immune responses against infectious agents, but their clinical use in this context is an area of ongoing research.

Are there any approved drugs targeting CD40 for clinical use?

As of my knowledge cutoff date in January 2022, there were no FDA-approved drugs specifically targeting CD40. However, clinical trials were ongoing for CD40-targeted therapies.

Can CD40-targeted therapies be used in combination with other cancer treatments?

Yes, CD40-targeted therapies are often investigated in combination with other treatments like checkpoint inhibitors or chemotherapy to enhance their effectiveness.

What are the potential side effects of CD40-targeted therapies in cancer treatment?

Side effects may include flu-like symptoms, cytokine release syndrome, and immune-related adverse events, which can be managed with supportive care and close monitoring.

Are there ongoing clinical trials exploring CD40-targeted therapies for atherosclerosis?

Research on CD40-targeted therapies for atherosclerosis is still in the experimental stages and not yet in advanced clinical trials.